Coloplast A/S/€COLOB
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Coloplast A/S
Coloplast A/S is a Danish multinational company that specializes in the development and manufacture of medical devices and services. The company's core business operates within the healthcare sector, offering products and services that focus on ostomy care, urology, continence care, and wound and skin care. Founded in 1957 and headquartered in Humlebæk, Denmark, Coloplast has established a strong presence in numerous countries, serving healthcare professionals and patients around the globe. Its strategic positioning is supported by a commitment to innovation and close collaboration with healthcare professionals to ensure the efficacy and safety of its offerings. Coloplast's competitive strengths derive from its comprehensive product portfolio and strong expertise in chronic care solutions.
Ticker
€COLOB
Sector
Primary listing
XGAT
Employees
16,814
Headquarters
Humlebæk, Denmark
Website
Coloplast A/S Metrics
BasicAdvanced
€18B
34.03
€2.42
0.55
€2.95
3.58%
Price and volume
Market cap
€18B
Beta
0.55
52-week high
€125.32
52-week low
€72.38
Average daily volume
2.8K
Dividend rate
€2.95
Financial strength
Current ratio
1
Quick ratio
0.612
Long term debt to equity
105.034
Total debt to equity
147.222
Dividend payout ratio (TTM)
121.67%
Interest coverage (TTM)
9.54%
Profitability
EBITDA (TTM)
1,140.609
Gross margin (TTM)
67.55%
Net profit margin (TTM)
14.62%
Operating margin (TTM)
27.19%
Effective tax rate (TTM)
34.33%
Revenue per employee (TTM)
€222,250
Management effectiveness
Return on assets (TTM)
9.82%
Return on equity (TTM)
24.72%
Valuation
Price to earnings (TTM)
34.031
Price to revenue (TTM)
4.975
Price to book
8.34
Price to tangible book (TTM)
-10.19
Price to free cash flow (TTM)
28.021
Free cash flow yield (TTM)
3.57%
Free cash flow per share (TTM)
2.939
Dividend yield (TTM)
3.58%
Growth
Revenue change (TTM)
5.95%
Earnings per share change (TTM)
-18.20%
3-year revenue growth (CAGR)
8.83%
10-year revenue growth (CAGR)
7.52%
3-year earnings per share growth (CAGR)
-6.96%
10-year earnings per share growth (CAGR)
1.97%
3-year dividend per share growth (CAGR)
5.01%
10-year dividend per share growth (CAGR)
11.36%
Bulls say / Bears say
Coloplast posted Q1 EBIT of DKK 1.54 billion, beating the Refinitiv consensus of DKK 1.48 billion, and announced a DKK 500 million share buyback, boosting shares by 5% that day (Reuters)
The company achieved 8% organic growth and sustained a 27% EBIT margin in Q1 2024/25, showing resilience in Ostomy, Continence, Voice & Respiratory, and Advanced Wound Care despite the Skin Care divestment (Nasdaq)
In August 2025 Coloplast launched its new 2030 strategy, reorganizing into two divisions (Chronic Care and Acute Care), creating a dedicated R&D function for Chronic Care, and forming a Wound & Tissue Repair unit to accelerate innovation and reduce time to market (Nasdaq)
Q2 organic growth slowed to 6%, with Ostomy Care growing only 4% and Interventional Urology declining 1% after a voluntary product recall, highlighting operational and regional pressures in critical segments (Nasdaq)
Coloplast lowered its FY24/25 organic growth forecast to about 7% from 8–9% and trimmed its EBIT margin guidance to 27–28%. This followed weaker-than-expected Q2 results and changes in management, triggering a 5% decline in shares (Investing.com)
Advanced Wound Dressings revenue dropped 2% in Q3 due to a proactive recall of Biatain® Adhesive foam dressings in China, underscoring ongoing quality control issues and sensitivity to regional regulatory risks (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Coloplast A/S stock?
Coloplast A/S (COLOB) has a market cap of €18B as of October 27, 2025.
What is the P/E ratio for Coloplast A/S stock?
The price to earnings (P/E) ratio for Coloplast A/S (COLOB) stock is 34.03 as of October 27, 2025.
Does Coloplast A/S stock pay dividends?
Yes, the Coloplast A/S (COLOB) stock pays dividends to shareholders. As of October 27, 2025, the dividend rate is €2.94995 and the yield is 3.58%. Coloplast A/S has a payout ratio of 121.67% on a trailing twelve-month basis.
When is the next Coloplast A/S dividend payment date?
The next Coloplast A/S (COLOB) dividend payment date is unconfirmed.
What is the beta indicator for Coloplast A/S?
Coloplast A/S (COLOB) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.